We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
Read MoreHide Full Article
Key Takeaways
TEM reported studies validating IPS, PurIST and xF diagnostics for improved cancer treatment decisions.
Tempus AI's IPS test predicted outcomes for ICI-treated patients better than TMB, MSI and PD-L1 biomarkers.
Tempus AI study showed PurIST helps guide first-line therapy in advanced pancreatic ductal adenocarcinoma.
Tempus AI (TEM - Free Report) continues to expand its leadership in precision medicine through a series of impactful research initiatives and clinical validations. Throughout 2025 and early 2026, the company reported several key studies highlighting the power of its AI-driven diagnostics to improve cancer treatment decisions.
In January 2026, TEM announced results from a new study demonstrating that its algorithmic test - Immune Profile Score (IPS) more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI) and PD-L1.
In September 2025, it announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST algorithmic diagnostic. The study provides the largest real-world evidence to date demonstrating PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC).
In April 2025, Tempus announced publication of its study “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants, including resistance mutations, identify clinically relevant biomarkers and monitor disease progression.
Peer Update
In November 2025, Illumina (ILMN - Free Report) announced results from a new study published in Nature, showing that whole-genome sequencing (WGS) can reveal much more about the genetic causes of common diseases than older genetic testing methods. The study found that rare variants identified through Illumina WGS with DRAGEN variant calling account for most of the missing heritability in complex human diseases and traits, including those linked to blood pressure and cholesterol.
In February 2025, Myriad Genetics (MYGN - Free Report) presented new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular Residual Disease) Test, Prolaris Prostate Cancer Prognostic Test and MyRisk Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification and inherited cancer risk assessment.
TEM Stock Price Performance
In the past year, Tempus’ shares have gained 15.8% against the industry’s 25.3% decline. The S&P 500 composite has improved 24.2% over the same period.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 5.67X compared with the industry median of 5.34X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has broadened to 56 cents from 42 cents.
View the Zacks #1 Rank List
Image: Bigstock
Tempus AI Expands Clinical Validation of AI-Powered Cancer Diagnostics
Key Takeaways
Tempus AI (TEM - Free Report) continues to expand its leadership in precision medicine through a series of impactful research initiatives and clinical validations. Throughout 2025 and early 2026, the company reported several key studies highlighting the power of its AI-driven diagnostics to improve cancer treatment decisions.
In January 2026, TEM announced results from a new study demonstrating that its algorithmic test - Immune Profile Score (IPS) more accurately predicts outcomes for patients receiving immune checkpoint inhibitors (ICIs) than conventional biomarkers, including tumor mutational burden (TMB) and microsatellite instability (MSI) and PD-L1.
In September 2025, it announced the publication of a study in JCO Precision Oncology validating the clinical utility of the company’s PurIST algorithmic diagnostic. The study provides the largest real-world evidence to date demonstrating PurIST’s ability to guide first-line treatment decisions and improve outcomes for patients with advanced pancreatic ductal adenocarcinoma (PDAC).
In April 2025, Tempus announced publication of its study “Analytical Validation of NGS-based Comprehensive Liquid Biopsy Assay for Therapy” in the Journal of Molecular Diagnostics. Data from this study supports the utility of xF+ as a non-invasive technique to detect actionable variants, including resistance mutations, identify clinically relevant biomarkers and monitor disease progression.
Peer Update
In November 2025, Illumina (ILMN - Free Report) announced results from a new study published in Nature, showing that whole-genome sequencing (WGS) can reveal much more about the genetic causes of common diseases than older genetic testing methods. The study found that rare variants identified through Illumina WGS with DRAGEN variant calling account for most of the missing heritability in complex human diseases and traits, including those linked to blood pressure and cholesterol.
In February 2025, Myriad Genetics (MYGN - Free Report) presented new data at the 2026 ASCO-GU conference supporting its Precise MRDTM (Molecular Residual Disease) Test, Prolaris Prostate Cancer Prognostic Test and MyRisk Hereditary Cancer Tests. These data highlight Myriad’s expanding role across the cancer care continuum, including ultra-sensitive molecular residual disease detection, prognostic stratification and inherited cancer risk assessment.
TEM Stock Price Performance
In the past year, Tempus’ shares have gained 15.8% against the industry’s 25.3% decline. The S&P 500 composite has improved 24.2% over the same period.
Image Source: Zacks Investment Research
Expensive Valuation
TEM currently trades at a forward 12-month Price-to-Sales (P/S) of 5.67X compared with the industry median of 5.34X.
Image Source: Zacks Investment Research
TEM Stock Estimate Trend
In the past 30 days, Tempus AI's loss per share estimate for 2025 has broadened to 56 cents from 42 cents.
Image Source: Zacks Investment Research
TEM currently carries a Zacks Rank #4 (Sell).
You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.